Clinical Trials

35 enrolled 10 charts

Other solid neoplasm

Malignant Solid Neoplasm

NCT05132582 2026-03-16

HER2CLIMB-05

654 enrolled

Breast Neoplasms

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

200 enrolled

Breast Neoplasms

NCT04266249 2026-03-02

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

2,175 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT07421141 2026-02-27

Opti-HER2

186 enrolled

Breast Neoplasms

NCT05593094 2026-02-25

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

210 enrolled

CNS

Brain Neoplasms

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

927 enrolled

Breast Neoplasms

NCT02320435 2026-02-12

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

154 enrolled

Other solid neoplasm

Solid Tumors

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Breast Neoplasms

NCT04158258 2026-02-12

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Active not recruiting

2,907 enrolled

Breast Neoplasms

NCT07407920 2026-02-12

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

120 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

500 enrolled

Solid Cancer

NCT07386938 2026-02-04

A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

246 enrolled

Breast Neoplasms

NCT04208178 2026-02-02

EPIK-B2

19 enrolled

Advanced HER2+Breast Cancer

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

198 enrolled

Breast Neoplasms

NCT05296798 2026-01-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

922 enrolled

Breast Neoplasms

NCT00781612 2025-12-24

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

720 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04538742 2025-12-08

DB-07

245 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04193059 2025-11-26

PANSY

1,560 enrolled

Breast Neoplasms

NCT04514419 2025-11-21

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

408 enrolled

Breast Neoplasms

NCT04733118 2025-11-20

PHERGAIN-2

393 enrolled

Breast Neoplasms

NCT04425018 2025-11-18

MARGOT

174 enrolled 19 charts

Breast Neoplasms

NCT05041842 2025-11-17

InTTercePT

53 enrolled

Metastatic Breast Cancer With a Isolated Brain Progression

NCT02827877 2025-11-14

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

18 enrolled 8 charts

Breast Neoplasms

NCT03716180 2025-09-22

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

100 enrolled

Breast Neoplasms

NCT05802225 2025-07-20

PREFER

398 enrolled

Breast Neoplasms

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

44 enrolled

Breast Diseases, Breast Neoplasms

NCT02436993 2025-07-14

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

120 enrolled

Breast Neoplasms

NCT01937117 2025-07-01

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

88 enrolled 15 charts

Breast Neoplasms

NCT04188548 2025-06-04

EMBER

500 enrolled

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT03161353 2025-04-23

PHERGain

377 enrolled

Breast Neoplasms

NCT03417544 2025-04-02

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

19 enrolled 26 charts

BreastCNS

HER2-positive Metastatic Breast Cancer

NCT03820141 2025-03-10

DTP

39 enrolled

Breast Neoplasms

NCT02326974 2025-03-05

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

164 enrolled 19 charts

Breast Neoplasms

NCT02625441 2025-02-11

BOLD-1

516 enrolled

Breast Neoplasms

NCT03125928 2025-01-10

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

16 enrolled

Phase 2/3 Active not recruiting

HER2-positive Breast Cancer

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

136 enrolled

HER2-positive Breast Cancer

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT01996267 2024-03-29

TRAIN-2

437 enrolled

Breast Neoplasms

NCT03595592 2024-03-06

APTneo

650 enrolled

Invasive Breast Cancer

NCT04398914 2022-03-31

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

216 enrolled

Phase 2/3 Active not recruiting

Breast Cancer Invasive

NCT02568839 2020-08-13

PREDIX HER2

202 enrolled